Bahl & Gaynor Inc. Has $53.58 Million Stake in Encompass Health Corporation $EHC

Bahl & Gaynor Inc. boosted its stake in shares of Encompass Health Corporation (NYSE:EHC) by 46.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 421,811 shares of the company’s stock after acquiring an additional 133,585 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Encompass Health were worth $53,578,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Alliancebernstein L.P. grew its holdings in shares of Encompass Health by 6.8% in the 2nd quarter. Alliancebernstein L.P. now owns 2,039,314 shares of the company’s stock worth $250,081,000 after purchasing an additional 129,276 shares during the last quarter. Geode Capital Management LLC grew its stake in Encompass Health by 0.5% during the second quarter. Geode Capital Management LLC now owns 1,773,547 shares of the company’s stock worth $217,526,000 after buying an additional 8,765 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Encompass Health by 5.3% during the third quarter. JPMorgan Chase & Co. now owns 1,410,335 shares of the company’s stock worth $179,141,000 after buying an additional 70,387 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Encompass Health by 57.8% in the third quarter. Thrivent Financial for Lutherans now owns 1,194,859 shares of the company’s stock valued at $151,544,000 after acquiring an additional 437,464 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its holdings in shares of Encompass Health by 31.5% in the 2nd quarter. Raymond James Financial Inc. now owns 1,143,642 shares of the company’s stock worth $140,245,000 after acquiring an additional 274,142 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Stock Up 0.5%

Shares of EHC opened at $107.70 on Monday. The business’s fifty day moving average price is $103.86 and its two-hundred day moving average price is $114.05. The firm has a market capitalization of $10.84 billion, a price-to-earnings ratio of 19.44, a PEG ratio of 2.07 and a beta of 0.70. Encompass Health Corporation has a 52 week low of $92.53 and a 52 week high of $127.99. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.08 and a current ratio of 1.08.

Encompass Health (NYSE:EHC) last issued its quarterly earnings results on Thursday, February 5th. The company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.17. The business had revenue of $3.09 billion for the quarter, compared to analyst estimates of $1.54 billion. Encompass Health had a return on equity of 18.20% and a net margin of 9.54%.The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.17 earnings per share. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. On average, analysts predict that Encompass Health Corporation will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Wednesday, April 1st will be paid a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, April 1st. Encompass Health’s dividend payout ratio (DPR) is 13.72%.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on EHC shares. Zacks Research cut Encompass Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 19th. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a research note on Sunday, January 18th. Finally, Barclays lifted their price target on Encompass Health from $150.00 to $153.00 and gave the company an “overweight” rating in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Encompass Health presently has a consensus rating of “Buy” and a consensus price target of $143.29.

Insider Buying and Selling at Encompass Health

In related news, CEO Mark J. Tarr sold 150,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $111.64, for a total transaction of $16,746,000.00. Following the completion of the sale, the chief executive officer directly owned 377,070 shares of the company’s stock, valued at $42,096,094.80. The trade was a 28.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.10% of the stock is currently owned by company insiders.

Encompass Health Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.